PFIZER, INC.

(PFE)
  Report
Delayed Nyse  -  04:03 2022-08-19 pm EDT
49.15 USD   +1.17%
08/19FDA asks Pfizer to test second Paxlovid course in patients with COVID rebound -Bloomberg News
RE
08/19Pfizer to Study Repeat Paxlovid Regimen at FDA Order, Details to be Finalized This Month
MT
08/19Canada OKs Pfizer-BioNTech COVID-19 booster dose for 5 to 11 year olds
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Basilea Announces Approval for Additional Formulation of Antifungal Cresemba(R) (Isavuconazole) in China

06/24/2022 | 01:15am EDT

Basilea Pharmaceutica Ltd. announced that its license partner, Pfizer Inc. (has received a Drug Approval License from the National Medical Products Administration (NMPA) in China, for the intravenous formulation of Cresemba(R) (isavuconazole) for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis. This is the second approved formulation for Cresemba in China, in addition to the oral formulation for invasive aspergillosis and invasive mucormycosis. invasive aspergillosis and invasive mucormycosis Invasive aspergillosis and invasive mucormycosis are life threatening mold infections that predominantly affect immunocompromised patients, such as patients with hematologic malignancies (blood cancer).

Both infections are associated with high morbidity and mortality. About isavuconazole (Cresemba) Isavuconazole is an intravenous (i.v.) and oral azole antifungal, commercialized under the trade name Cresemba. Basilea has entered into several license and distribution agreements for isavuconazole covering the United States, Europe, China, Japan, Latin America, Asia-Pacific, the Middle East and North Africa region, Canada, Russia, Turkey and Israel.

In the 27 European Union member states, as well as in Iceland, Liechtenstein, Norway and the U.K., isavuconazole is approved for the treatment of adult patients with invasive aspergillosis and for the treatment of adult patients with mucormycosis for whom amphotericin B is inappropriate.(2) In China, the oral and intravenous formulations are approved for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis. Isavuconazole is also approved in the United States and several additional countries in Europe and beyond.(3) It has orphan drug designation in the U.S., Europe and Australia for its approved indications. About Basilea Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland.


© S&P Capital IQ 2022
All news about PFIZER, INC.
08/19FDA asks Pfizer to test second Paxlovid course in patients with COVID rebound -Bloomber..
RE
08/19Pfizer to Study Repeat Paxlovid Regimen at FDA Order, Details to be Finalized This Mont..
MT
08/19Canada OKs Pfizer-BioNTech COVID-19 booster dose for 5 to 11 year olds
RE
08/19Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare ..
BU
08/17GSK Says No Payment Made After Zantac Plaintiff Drops Lawsuit
MT
08/17Moderna - Evidation Enables First of Its Kind Moderna Study to Track COVID Vaccine Resp..
AQ
08/17GSK shares ease after plaintiff in first Zantac lawsuit drops case
RE
08/17GSK Says First US Plaintiff to Drop Zantac Case
DJ
08/16Plaintiff in first Zantac lawsuit set for trial drops case
RE
08/16Ambrx Biopharma Names Kate Hermans Interim CEO
MT
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 102 B - -
Net income 2022 32 675 M - -
Net cash 2022 11 522 M - -
P/E ratio 2022 8,72x
Yield 2022 3,30%
Capitalization 276 B 276 B -
EV / Sales 2022 2,60x
EV / Sales 2023 3,30x
Nbr of Employees 79 000
Free-Float 59,0%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 49,15 $
Average target price 56,53 $
Spread / Average Target 15,0%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-16.77%275 847
JOHNSON & JOHNSON-1.03%438 468
ELI LILLY AND COMPANY14.66%300 939
ROCHE HOLDING AG-15.60%275 743
ABBVIE INC.4.35%249 814
NOVO NORDISK A/S2.97%233 688